Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added Overall Survival (OS) as an endpoint with follow-up up to 3 years and introduced multiple immune cell biomarkers (CD56, CD19, CD14, CD8, CD4, CD3, CD45) at various treatment-cycle timepoints. Removed prior CD8+ and CD3+ cell change endpoints measured at baseline and early post-treatment.
    Difference
    8%
    Check dated 2026-02-18T07:22:37.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-status notice and the prior Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T05:37:57.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about potential data not being up to date due to a lapse in government funding and updated the site revision from 3.4.0 to 3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T05:34:04.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now includes a glossary toggle and updated metadata labels, including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. The previous labels such as 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed or renamed.
    Difference
    0.2%
    Check dated 2026-01-28T03:11:44.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4. No substantive trial details or documents appear to be changed.
    Difference
    0.1%
    Check dated 2026-01-14T01:42:41.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Locations now include Pennsylvania, adding essential site information; the revision is updated to v3.3.3 and the previous Pennsylvania Locations entry and HHS Vulnerability Disclosure are removed.
    Difference
    0.2%
    Check dated 2025-12-23T17:26:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.